We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $791M
1-Year Est. Return 245.83%
This Fund
S&P 500
This Quarter Est. Return
+23.31%
1 Year Est. Return
+245.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$791M
AUM Growth
+$204M
Cap. Flow
+$24.2M
Cap. Flow %
3.06%
Top 10 Hldgs %
37.34%
Holding
211
New
67
Increased
36
Reduced
24
Closed
63

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$35.2M
2
UTHR icon
United Therapeutics
UTHR
+$14.5M
3
ABVX
Abivax
ABVX
+$9.93M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$9.38M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.02M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$10.4M
2
TERN
Terns Pharmaceuticals
TERN
+$9.58M
3
TGTX icon
TG Therapeutics
TGTX
+$8.47M
4
INCY icon
Incyte
INCY
+$7.74M
5
JNJ icon
Johnson & Johnson
JNJ
+$7.4M

Sector Composition

Rank Sector Weight
1 Miscellaneous 66.57%
2 Healthcare 33.4%
3 Consumer Discretionary 0.02%
4 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PYXS icon
101
CALL
Pyxis Oncology
PYXS
$324M
$1.17M 0.15%
+388,200
New +$742K
XERS icon
102
Xeris Biopharma Holdings
XERS
$1.56B
$1.05M 0.13%
132,746
– –
PHVS icon
103
Pharvaris
PHVS
$2.47B
$1.01M 0.13%
29,321
– –
HRMY icon
104
Harmony Biosciences
HRMY
$2.46B
$978K 0.12%
26,864
-66,000
-71% -$2.08M
RNAC icon
105
Cartesian Therapeutics
RNAC
$280M
$907K 0.11%
+87,057
New +$645K
AQST icon
106
CALL
Aquestive Therapeutics
AQST
$670M
$893K 0.11%
+214,600
New +$903K
RIGL icon
107
Rigel Pharmaceuticals
RIGL
$909M
$893K 0.11%
+22,816
New +$704K
SMMT icon
108
Summit Therapeutics
SMMT
$14B
$874K 0.11%
+60,000
New +$1.06M
PGEN icon
109
Precigen
PGEN
$2.54B
$771K 0.1%
135,293
+80,000
+145% +$346K
DFTX
110
Definium Therapeutics
DFTX
$5.12B
$727K 0.09%
+15,451
New +$382K
PTHS
111
Pelthos Therapeutics
PTHS
$93.2M
$700K 0.09%
24,773
– –
PEPG icon
112
PepGen
PEPG
$215M
$672K 0.08%
373,284
+222,359
+147% +$362K
HELP
113
CALL
Cybin Inc
HELP
$893M
$661K 0.08%
+100,000
New +$500K
VYGR icon
114
CALL
Voyager Therapeutics
VYGR
$216M
$525K 0.07%
150,000
– –
CGON icon
115
CALL
CG Oncology
CGON
$6.62B
$519K 0.07%
+7,300
New +$477K
ELVN icon
116
Enliven Therapeutics
ELVN
$4.35B
$508K 0.06%
10,000
+9,755
+3,982% +$414K
CNTB
117
Connect Biopharma Holdings
CNTB
$116M
$469K 0.06%
196,985
-3,705
-2% -$8.98K
LRMR icon
118
Larimar Therapeutics
LRMR
$398M
$447K 0.06%
146,637
-20,000
-12% -$79.4K
ELTX icon
119
CALL
Elicio Therapeutics
ELTX
$63.3M
$438K 0.06%
+112,100
New +$1.13M
ELTX icon
120
PUT
Elicio Therapeutics
ELTX
$63.3M
$391K 0.05%
+100,000
New +$1M
CLRB icon
121
Cellectar Biosciences
CLRB
$22.4M
$385K 0.05%
+138,341
New +$387K
FHTX icon
122
Foghorn Therapeutics
FHTX
$292M
$327K 0.04%
66,908
-13,036
-16% -$57.8K
AYTU icon
123
AYTU BioPharma
AYTU
$23.7M
$319K 0.04%
148,546
-204,531
-58% -$483K
OCGN icon
124
Ocugen
OCGN
$461M
$306K 0.04%
200,000
– –
INO icon
125
CALL
Inovio Pharmaceuticals
INO
$148M
$303K 0.04%
275,200
+200,000
+266% +$237K
3 4
5
6 7

Similar funds

KAS
Kemnay Advisory Services New York $791M AUM 14.14% 1-Year Est. Return
FSAG
Financial Solutions Advisory Group Chicago, Illinois $791M AUM
KAS
KPP Advisory Services Louisville, Kentucky $791M AUM 28.5% 1-Year Est. Return
BSSFA
Baron Silver Stevens Financial Advisors Boca Raton, Florida $791M AUM 18.81% 1-Year Est. Return
GUB
Golden Unicorn BVI Road Town $792M AUM 60.81% 1-Year Est. Return
EA
Enclave Advisors Austin, Texas $790M AUM 21.99% 1-Year Est. Return
BBES
Buffalo Business & Estate Services Orchard Park, New York $793M AUM
GEA
Glen Eagle Advisors Kingston, New Jersey $793M AUM 21.06% 1-Year Est. Return

Diadema Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Diadema Partners held 211 positions worth $791M, up 35% from $588M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Diadema Partners deployed $24.2M of net new capital in Q2 2026, opening 67 new positions and adding to 36 existing holdings. Its largest new stake was Amgen: 102,701 shares worth $215K.

By sector, the portfolio is most concentrated in Miscellaneous at 67% of assets, up from 62% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Johnson & Johnson, an estimated $7.4M trimmed.

  • Diadema Partners's largest Q2 2026 buy was Amgen: 102,701 shares worth $215K.
  • Diadema Partners added most to United Therapeutics in Q2 2026, an estimated $14.5M increase.
  • Diadema Partners's biggest Q2 2026 reduction was Johnson & Johnson, cutting an estimated $7.4M.
  • Diadema Partners fully exited Jazz Pharmaceuticals in Q2 2026, selling an estimated $10.4M.
  • Diadema Partners's ten largest holdings make up 37% of its $791M portfolio in Q2 2026.
  • Diadema Partners opened 67 new positions and closed 63 in Q2 2026.
  • Diadema Partners's portfolio value rose 35% quarter-over-quarter to $791M.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.